TY - JOUR T1 - 25-Year Follow-up of HIV-positive Patients with Benign Lymphoepithelial Cysts of the Parotid Glands: A Retrospective Review JF - Anticancer Research JO - Anticancer Res SP - 4927 LP - 4932 VL - 33 IS - 11 AU - WALEED F. MOURAD AU - REBEKAH YOUNG AU - RAFI KABARRITI AU - DUKAGJIN M. BLAKAJ AU - RANIA A. SHOURBAJI AU - JONATHAN GLANZMAN AU - SHYAMAL PATEL AU - NITIN OHRI AU - RAVINDRA YAPARPALVI AU - JONATHAN J. BEITLER AU - SHALOM KALNICKI AU - MADHUR K. GARG Y1 - 2013/11/01 UR - http://ar.iiarjournals.org/content/33/11/4927.abstract N2 - Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity. ER -